

POAC funded Fosfomycin for Multi-Resistant UTI



BACKGROUND

Multi-resistant organisms are an increasing problem in NZ, particularly in the Auckland area.

Oral *Fosfomycin trometamol* is indicated in the treatment of urinary tract infections due to a gram negative organism that is resistant to commonly prescribed oral antibiotics. For example, oral *Fosfomycin* has been used to treat uncomplicated ESBL positive *E. coli* and *Klebsiella* UTI in primary care thus avoiding an acute hospital admission for IV antibiotics. Gram negative bacilli expected to be *Fosfomycin* resistant include *Morganella*, *Acinetobacter* and *Stenotrophomonas*.

Fosfomycin is not licensed or funded in NZ but is available from MMH, ACH and NSH pharmacies at a cost to the patient of approximately \$90 per dose.

Fosfomycin is usually administered as a single (or repeated) oral megadose (ie 3g on day 1 +/- 3g on day 4). Each sachet of *Fosfomycin* should be dissolved in approx half a cup of cool water or juice. It is well tolerated and has a low incidence of harmful side-effects. However, development of bacterial resistance under therapy may occur which makes *Fosfomycin* unsuitable for sustained monotherapy of severe infections.

Pre-requisites:

Consultant recommendation: endorsement must be obtained from either an Infectious Diseases Consultant or Clinical Microbiologist at MMH, ACH, NSH, Labtests or DML.

Drug collection: the drug must be collected from MMH, ACH or NSH pharmacy

POAC Case No: the patient must be provided with a prescription which includes the POAC case number and name of recommending Consultant.

POAC funding: a POAC administration fee may be claimed.

Attachments:

PATIENT INFO LEAFLET INCLUDING DIRECTIONS TO HOSPITAL PHARMACIES